MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT
Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.350
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV